How to Restart GLP-1 After a Break: 2026 Rules by Drug

Wegovy comes in two forms with two different rules, so step one is knowing which you take. For the injection, missing two or more shots in a row is the label's signal to step down and re-titrate. For the tablets, you skip the missed dose and take the next one the following day.

If you missed one Wegovy injection: the rule is based on how close your next dose is. More than 48 hours away? Take the missed dose now, then get back on your usual day. Less than 48 hours away? Skip it and take your next scheduled dose. Right around the 48-hour line? Don't overthink it — a quick message to your pharmacist or prescriber beats guessing.

If you missed two or more Wegovy injections in a row: the current label says to reinitiate dose escalation at a lower dose to reduce the stomach side effects that come with restarting. It doesn't name the exact lower dose — that's your prescriber's call, and it usually depends on how many weeks you missed. Wegovy's patient instructions also point people who've missed two or more consecutive weeks toward contacting their healthcare provider before resuming.

If you take Wegovy tablets: miss one, skip it, take the next dose the next day. Don't double up, and don't apply the injection's rule to the pill.

A couple of quick notes: if you're changing which day you inject, make sure your previous injection was at least 2 days earlier. And Wegovy HD is one of the injection presentations, so the Wegovy injection rule applies to it — there's no separate HD restart formula in the current label.

Ozempic and oral semaglutide are diabetes-labeled, so a restart isn't just about nausea — it's also about blood sugar. For Ozempic injection, take a missed dose within 5 days; after that, skip it and resume schedule. For Rybelsus, skip a missed tablet and take the next dose the following day. Neither label names an exact dose for a multi-week gap.

Ozempic injection, one missed dose: you have a 5-day window from the missed dose to take it. Past 5 days, skip it and take your next dose on the regular day.

Ozempic after several missed weeks: the missed-dose section doesn't give an exact restart dose. Don't assume the 0.25 mg starting dose is automatically your restart dose — and don't assume you can jump back to where you left off. Your prescriber weighs your diabetes plan and how you tolerated the medication before.

Rybelsus, one missed tablet: skip it, resume the next day. One note if you're switching semaglutide products: oral and injectable semaglutide use completely different milligram scales (Rybelsus is 3–14 mg; Ozempic is 0.25–2 mg), so they are not a same-milligram swap. Any switch between products is a prescriber-directed conversion, not a restart at "the same number."

If your blood sugar is climbing during the break: follow the glucose-monitoring plan your clinician already gave you. Don't change insulin or other diabetes medicines based on a web page. If your readings run high (or you feel off), reach out to your diabetes clinician promptly.

Zepbound and Mounjaro both contain tirzepatide but have different FDA-approved uses, and they share the same timing rule. Take a missed dose within 4 days (96 hours); after that, skip it and resume schedule, keeping at least 72 hours between doses. Neither label names an exact dose for a longer break — so "just restart at 2.5 mg" is not a universal rule.

One missed dose: if it's been 4 days or less, take it. More than 4 days, skip it and take your next dose on the regular day. Don't put two doses within 72 hours of each other.

Two or more missed doses / a longer gap: the labels don't state one exact restart dose. The honest move is to let your prescriber choose the step-down based on your prior dose and how you tolerated it — not to copy a number off the internet.

Why we don't just tell everyone "restart at 2.5 mg": 2.5 mg is the starting dose for people beginning treatment. After a break, some people do restart low and re-titrate — but that's a clinical decision, not a label rule.

If you have diabetes: tirzepatide affects blood sugar, and combining it with insulin or a sulfonylurea can raise the risk of a low. Don't adjust those medicines on your own during a break — loop in your clinician.

These four are the clearest proof that a single "GLP-1 restart rule" doesn't exist. Saxenda and Victoza name an exact restart dose (0.6 mg) after more than 3 days. Trulicity gives a routine 72-hour window but no long-gap dose. Foundayo tells you to step down after 7 consecutive missed doses — without naming the dose.

Saxenda (daily weight-loss shot): miss a dose, just resume the next day — no catch-up. But if more than 3 days have passed since your last shot, the label says restart at 0.6 mg daily and step back up. Because Saxenda is daily and clears fast, a short gap is what triggers that reset. This is an actual label instruction, not a guess.

Victoza (daily diabetes shot, same drug as Saxenda): same idea — resume the next day for a normal miss, but after more than 3 days, restart at 0.6 mg once daily, then step up as your clinician directs.

Trulicity (weekly diabetes shot): if there are at least 72 hours until your next dose, take the missed one; otherwise skip it. The missed-dose section doesn't spell out a dose for a long break — that's a prescriber conversation.

Foundayo (the newer daily pill, orforglipron): miss a dose, take it as soon as you remember, and don't double up. But if you miss 7 or more consecutive doses, the label says restart the step-up schedule at a lower dose. It doesn't print the exact number, so your prescriber sets it.

If you're re-titrating, watch two things beyond the dose: birth control and your other medicines. Tirzepatide (Zepbound, Mounjaro) can make oral birth control pills less effective, so its label says to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase. A restart that re-escalates repeats that window. Foundayo has a similar rule for 30 days. Semaglutide labels (Ozempic, Wegovy) don't include this requirement.

Here's why it matters on a restart specifically: if you step down and then climb back up, each dose increase can briefly reduce how well an oral contraceptive is absorbed. For tirzepatide, the label advises switching to a non-oral method (like an IUD, implant, patch, or ring) or adding a barrier method such as condoms — for 4 weeks after you restart and for 4 weeks after each step up. For Foundayo, that window is 30 days after starting and after each increase. Non-oral birth control isn't affected by this.

Foundayo also has other interaction rules: its label says not to exceed simvastatin 20 mg daily when the two are used together, and it gives instructions for medicines that block or speed up a liver enzyme called CYP3A4. So when you restart, tell your prescriber every prescription, over-the-counter medicine, and supplement you take — not just the GLP-1.

If your new vial has a different concentration than before: do not calculate a new dose yourself. Get a fresh milligram-to-units instruction from your prescriber or the pharmacy that filled it.

If you don't know where a vial came from, or it wasn't stored right: don't use it. The FDA has warned about fake and mislabeled products in this space.

And a line we hold ourselves to: compounded semaglutide and tirzepatide are not FDA-approved, are not "generic" versions of Wegovy or Ozempic, and shouldn't be treated as automatically interchangeable with brand-name drugs or governed by a brand's pen instructions.

The early stomach stuff can return — but no honest page can promise a set timeline or predict how strong it'll be from the gap alone. Nausea, vomiting, diarrhea, constipation, and that "too full" feeling can show up again, especially around restarting and dose increases. For many people it's manageable and eases as the body re-adjusts, but severe or lasting symptoms need medical attention, not another guessed dose.

The returning side effects are usually the same ones from the beginning: nausea, vomiting, diarrhea, constipation, and reduced appetite. How intense they are varies from person to person — it's not something you can read off how many weeks you were away.

A break doesn't "use up" the medication or prove it won't work for you again — but how you respond after restarting varies from person to person, and the well-known trials measured what happens when people stop, not restart. It's also completely normal to have regained some weight while you were off. That's the biology of the condition, not a personal failure — and it's a big reason people restart.

"Did a break 'reset' my body so it'll work better (or worse)?" There's no reliable human rule that a pause resensitizes you or guarantees a stronger response. Don't take an intentional break hoping to supercharge the restart — that's not an established strategy. What is true: appetite and "food noise" tend to return as the drug clears, and how quickly varies.

"Did I lose all my progress?" Some weight regain after stopping is common and well-documented — which is exactly why these are chronic-condition medications, not short courses. In the STEP 1 extension, people regained about two-thirds of the weight they'd lost within a year of stopping semaglutide. In SURMOUNT-4, people lost about 21% of their weight over 36 weeks on tirzepatide; those switched to a placebo then regained about 14% over the next year, while those who stayed on kept losing. Read those honestly: they show what happens after treatment is withdrawn — not how well someone responds after restarting. Regain is expected when treatment stops, it isn't a character flaw.

If it doesn't feel as strong at first, that usually has a plain explanation: you're on a lower restart dose, or a different product or concentration, or your body's simply re-adjusting. That's a reason to check the ramp-up plan with your prescriber — not to increase the dose early.